Q2 FY2026 EarningsQ2 FY26 beat consensus across key metrics: revenue $49.1M vs. $48.9M expected, and GAAP EPS -$0.03 vs. -$0.04 expected. Vafseo revenue ramped significantly to $21.3M (+60.4% YoY), partially mitigating the 46.0% YoY decline in Auryxia sales following Teva's generic entry in March 2026. Management implemented a restructuring plan involving a 13% headcount reduction to optimize commercial operations ahead of the critical 2027 TDAPA exit for Vafseo.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Akebia Therap(AKBA) the Revenue is 49.13 M (-21.36%), Beat estimate;the EBIT is -4.381 M (-131.1%), Beat estimate;the EPS is -0.03 (--%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.05B21.36%
0.05B21.79%
+0.00B0.43%
EBITExceed expectations
-0.00B131.10%
-0.01B162.39%
+0.00B31.29%
EPSExceed expectations
-0.03--
-0.044--
+0.0140--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf